Nephrology Forum

Kidney International (1997) 52, 843–861; doi:10.1038/ki.1997.403

Hepatitis C in renal transplanation

Gregory G Vosnides Principal discussant:1

1Laiko General Hospital, Athens, Greece

Top

References

  1. Ishak K, Baptista A, Bianchi L, Callea F, Degroote J, Gudat F, Denk H, Desmet V, Korb G, Macsween RNM, Phillips MJ, Portmann BG, Poulsen H, Schemeuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699, 1995 | Article | PubMed | ISI | ChemPort |
  2. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 244:359–362, 1989 | Article | PubMed | ISI | ChemPort |
  3. Alter HJ, Purcell RH, Shih SW, Melpolder JC, Houghton M, Choo Q-L, Kuo G: Detection of antibody to Hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494–1500, 1989 | PubMed | ISI | ChemPort |
  4. Aach RD, Stevens CE, Hollinger FB, MOSLEY JW, Peterson DA, Taylor PE, Johnson RG, Barbosa LH, Nemo GJ: Hepatitis C virus infection in post-transfusion hepatitis: An analysis with the first and second generation assays. N Engl J Med 325:1325–1329, 1991
  5. Miller PH, Purcell RH: Hepatitis C virus shares aminoacid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci USA 87:2050–2061, 1990
  6. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ: Genetic organization and diversity of the hepatitis C virus. Proc Nat Acad Sci USA 88:2451–2455, 1991
  7. Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayawa H: Structure and organization of the hepatitis C genome isolated from human carriers. J Virol 65:1105–1113, 1991 | PubMed | ISI | ChemPort |
  8. Wang C, Sarnow P, Siddique A: Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol 67:3338–3344, 1993 | PubMed | ISI | ChemPort |
  9. Houghton M, Weiner A, Han J, Kuo G, Choo Q-L: Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology 14:381–388, 1991 | Article | PubMed | ChemPort |
  10. van der Poel CL, Guypers HT, Reesink HW: Hepatitis C virus six years on. Lancet 344:1475–1479, 1994
  11. Kato N, Ootsuyama Y, Tanaka T, Nakagawa N, Nakazawa T, Muraiso K, Ohkoshi S, Hijikata M, Shimotohna K: Marked sequence diversity in the putative envelope protein of hepatitis C viruses. Virus Res 22:107–123, 1992
  12. Simmonds P, Albert A, Alter HJ, Bonino F, Daniel W, Bradley CB, Brechot C, Brouwer T, Chan S-W, Chayma K, et al: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324, 1994 | Article | PubMed | ChemPort |
  13. Kuo G, Choo Q-L, Alter JH, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Aleter MJ, Stevens CE: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364, 1989 | Article | PubMed | ISI | ChemPort |
  14. Brown D, Dusheiko G: Hepatitis C virus. Diagnosis, in Viral Hepatitis, Scientific Basis and Management, edited by Zuckerman AJ, Thomas HC, London, Churchill Livingstone, 1993, p 283
  15. Courouce AM, Bouchardeau F, Girault A, Le Marrec N: Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 343:853–854, 1994
  16. Busch MP, Tobler LH, Francis B, Lee SR: Reinstatement of donors who test false-positive in second-generation hepatitis C virus enzyme immunoassay should await availability of licensed third-generation tests. Transfusion 34:278, 1994
  17. Evans CS, Tobler L, Polito A, Stewart J, Chien D, Wilber J, Quan S, Delaney S, Kuo G, Busch MP: Comparative evaluation of hepatitis C virus antibody supplemental test systems. Transfusion 32:408–414, 1992
  18. Weiner AJ, Kuo G, Bradley DW, Bonino F, Saracco G, Lee C, Rosenblatt J, Choo Q-L, Houghton M: Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet 335:1–3, 1990 | Article | PubMed | ISI | ChemPort |
  19. Kato N, Yokorusa O, Omata M, Hosada K, Ohto M: Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 86:1764–1767, 1990
  20. Bukh J, Purcell RH, Miller RH: Importance of primers selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 89:187–191, 1992
  21. Sugitani M, Inchaupse G, Shindo M, Prince AM: Sensitivity of serological assays to identify blood donors with hepatitis C viremia. Lancet 339:1018–1019, 1992
  22. Busch MP, Wilber JC, Johnson PJ, Tobler L, Evans CS: Impact of specimen handling and storage on detection of hepatitis C virus RNA. Transfusion 32:420–425, 1992
  23. Lau J, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504, 1993 | Article | PubMed | ISI | ChemPort |
  24. Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, Chang CA: Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 24:197–200, 1991 | PubMed | ChemPort |
  25. Sanchez-Pescador R, Sheridar PJ, Detmer JJ, Hunt WP, Chan CS, Wright T, Okano A, Wilber JC, Neuwald PD, Urdea MS: Quantitative detection of HCV RNA in human sera using a chemiluminescence signal amplification oligonucleotide probe assay. (abstract). Hepatology 16:588, 1992
  26. Valderrábano F, Jones EHP, Mallick NP: Report on management of renal failure in Europe. XXIV, 1993. Nephrol Dial Transplant 10(suppl 5):12, 1995
  27. Valderrábano F, Bertoux FC, Mehls O: Report on the management of renal failure in Europe. XXV, 1994. Nephrol Dial Transplant 11 (suppl 5):16–17, 1995
  28. Tokars JI, Alter MJ, Favero MS, Mover LA, Bland LA: National surveillance of dialysis associated diseases in the United States, 1991. ASAIO Journal 39:966–975, 1993
  29. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV: The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 112:958–960, 1990
  30. Jeffers LJ, Ferez CO, De Medina MD, Ortiz-Interian CJ, Schiff ER, Reddy KR, Jimenez M, Bourgoignie JJ, Vaamonde CA, Duncan R, Houghton M, Choo Q-L, Kuo G: Hepatitis C infection in two urban hemodialysis units. Kidney Int 38:320–322, 1990
  31. Niu MT, Coleman PJ, Alter MJ: Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 22:568–573, 1993
  32. Chan TM, Lok ASF, Cheng IKP, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. Hepatology 17:5–8, 1993 | Article | PubMed | ISI | ChemPort |
  33. Kuhns M, De Medina M, Mcnamara A, Jeffers LJ, Reddy KR, Silva M, Ortiz-Interian C, Jimenez M, Schiff ER, Ferez G: Detection of hepatitis C virus RNA in hemodialysis patients. J Am Soc Nephrol 4:1491–1497, 1994
  34. Chauveau P, Courouce AM, Lemarec N, Naret C, Poignet JL, Girault A, Ramdame M, Delons S: Antibodies to hepatitis C virus by second generation test in hemodialyzed patients. Kidney Int 43:5149–5152, 1993
  35. Pols S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F, Berthelot P, Brichot C: Hepatitis C virus RNA in anti-HCV positive hemodialysis patients: Significance and therapeutic implications. Kidney Int 44:1097–1100, 1993
  36. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH: High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 168:1343–1348, 1993 | PubMed |
  37. Courouce AM, Bouchardeau F, Chaveau P, Le Marrec N, Girault A, Zins B, Naret C, Poignet JL: Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third generation assays). Nephrol Dial Transplant 10:234–239, 1995
  38. Katsoulidou A, Psichogiou M, Vaindirli E, Boletis J, Vosnides G, Skoutelis G, Hatzakis A: Immunological and virological events during the incubation of the hepatitis C virus (HCV) infection in hemodialysis patients. XXXII Cong ERA-EDTA, Athens, June 1995, p 209
  39. Lau JYN, Davis GL, Brunson ME, Qian KP, Kin HJ, Quan S, Dinello R, Polito AJ, Scornik JC: Hepatitis C virus infection in kidney transplant recipients. Hepatology 18:1027–1031, 1993
  40. Fernandez JL, Delpino N, Lef L, Valtuille R, Berridi J, Rendo P, Viola L: Serum hepatitis C virus RNA in anti-HCV negative hemodialysis patients. Dial Transplant 25:14–18, 1996
  41. Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann G, Petermann D, Muller C: HBV and HCV genome in peripheral blood mononuclear cells in patients undergoing hemodialysis. Kidney Int 48:1967–1971, 1995
  42. Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokke-Gaard N, Rasmussen LS, Lassen A, Krogsgaard K: Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney Int 43:1353–1356, 1993
  43. Dussoll B, Chicheportiche C, Cantaloube JF, Roubicek C, Biagini P, Berthezene P, Berland Y: Detection of hepatitis C infection by polymerase chain reaction among hemodialysis patients. Am J Kidney Dis 22:574–580, 1993
  44. Muller GY, Zabaleta ME, Arminio A, Colmenares CJ, Capriles FI, Bianco NE, Machado IV: Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int 41:1055–1058, 1992 | PubMed |
  45. Boletis J, Miriagou B, Stathakis CH, Goumenos D, Papastathi H, Stamatiadis D, Vafiadi I, Kostakis A, Hatzakis A, Vosnides G: Antibodies against hepatitis C virus among hemodialysis patients in Greece, in Recent Advances in Chemotherapy (Proc 17th Int Cong Chemotherapy, edited by Adam D, Lode H, Rubinstein E, Munich, Futuramed Publishers, 1991, p 1778
  46. Hardy NM, Sandroni S, Danielson S, Wilson WJ: Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 38:44–48, 1992 | PubMed |
  47. Yamaguchi K, Nishumura Y, Fukuoka N, Machida J, Ueda S, Kusumoto Y, Futami G, Ishii T, Takatsuki K: Hepatitis C virus antibodies in hemodialysis patients. Lancet 335:1409–1410, 1990
  48. Neto MC, Draibe SA, Silva AEB, Ferraz ML, Granato C, Pereira CAP, Sesso RC, Gaspar AMC, Ajzen H: Incidence and risk factors for hepatitis B and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transpl 10:240–246, 1995
  49. Besso L, Rovere A, Peano G, Menardi G, Fenoglio M, Fenoglio S, Ghezzi PM: Prevalence of HCV antibodies in a uremic population undergoing maintenance dialysis therapy and in the staff members of the dialysis unit. Nephron 61:304–306, 1992
  50. Chan TM, Lok ASF, Cheng IKP: Hepatitis C infection among dialysis patients: A comparison between patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 6:944–947, 1991
  51. Huang CC, Wu MS, Lin DY, Liaw YF: The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 12:31–33, 1992
  52. Gladziwa U, Schlipkoter U, Lorbeer B, Cholmakow K, Roggendorf M, Sieberth HG: Prevalence of antibodies to hepatitis C virus in patients on peritoneal dialysis. Clin Nephrol 40:46–52, 1993
  53. Barril G, Traver JA: Prevalence of hepatitis C virus in dialysis patients in Spain. Nephrol Dial Transplant 10 (suppl 6):78–80, 1995
  54. Pereira BJG, Wright TL, Schmit CH, Bryan CF, Cheung RC, Cooper S, Hsu H, Heyn-Lamb R, Light JA, Norman DJ, Vav Thiel DH, Werner BG, Wright CE, Levey AS: Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: A U.S. National Collaborative Study. Kidney Int 46:886–892, 1994 | PubMed |
  55. Roth D, Fernandez JA, Babischkin S, De Mattos A, Buck BE, Quan S, Olson L, Burke GW, Nery JR, Esquenazi V, Schiff ER, Miller J: Transmission of hepatitis C virus with solid organ transplantation: Incidence and clinical significance. Transplant Proc 25:1476–1477, 1993
  56. Tesi RJ, Waller MK, Morgan CJ, Delaney S, Elkhammas EA, Henry ML, Ferguson RM: Use of low-risk HCV positive donors for kidney transplantation. Transplant Proc 25:1472–1473, 1993
  57. Mendez R, Aswad S, Bogaard T, Khetan U, Asai P, Martinez A, Flores N, Mendez RG: Donor hepatitis C antibody virus testing in renal transplantation. Transplant Proc 25:1487–1490, 1993
  58. Pereira BJG, Milford EL, Kirkman RL, Quan S, Sayre KR, Johnson PJ, Wilber JC, Levey AS: Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 327:910–915, 1992
  59. Pereira BJG, Wright TL, Schmid CH, Levey AS: A controlled study of hepatitis C transmission by organ transplantation. Lancet 345:484–487, 1995
  60. Roth D, Fernandez JA, Babischkin S, De Mattos A, Buck BE, Quan S, Olson L, Burke GW, Nery JR, Esouenazi V, Schiff ER, Miller J: Detection of hepatitis C virus infection among cadaver organ donors: Evidence for low transmission of disease. Ann Intern Med 117:470–475, 1992 | PubMed | ChemPort |
  61. Roth D: Hepatitis C virus infection and the renal allograft recipient. Nephron 71:249–253, 1995
  62. Tesi RJ, Waller K, Morgan CJ, Delaney S, Elkhammas EA, Henry ML, Ferguson RM: Transmission of hepatitis C by kidney transplantation-The risks. Transplantation 57:826–831, 1994
  63. Ramos EL, Kasiske BL, Alexander SR, Danovitch GM, Harmon WE, Kahana L, Kiresuk TJ, Neylan JF: The evaluation of candidates for renal transplantation. Transplantation 57:490–497, 1994
  64. Roth D: Hepatitis C virus: The nephrologist's view. Am J Kidney Dis 25:3–16, 1995 | PubMed |
  65. Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel P: Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation 55:674–675, 1993
  66. Zucker K, Cirocco R, Roth D, Olson L, Burke GW, Nery J, Esquenazi V, Miller J: Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 57:832–840, 1994
  67. Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Fuertes A, Ercilla G, Bruguera M, Andreu J, Carretero P, Rodicio JL, Levey AS, Pereira BJG: Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 47:236–240, 1995 | PubMed | ChemPort |
  68. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH: Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140, 1992 | Article | PubMed | ISI | ChemPort |
  69. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P: Hepatitis C in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343:388–390, 1994 | Article | PubMed | ISI | ChemPort |
  70. Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Ercilla G, Oppenheimer F, Vilardell J, Bruguera M, Rodicio JL, Wright TL, Levey AS, Pereira BJG: Hepatitis C viral levels and clinical course among anti-HCV positive recipients of kidneys from anti-HCV positive donors. 7th Cong Eur Soc Organ Transplantation (ESOT), Vienna, 1995, p 136
  71. Pereira BJG: Hepatitis C infection and post-transplantation liver disease. Nephrol Dial Transplant 10(suppl l):58–67, 1995
  72. Mahony JF: Long-term results and complications of transplantation: The kidney. Transplant Proc 21:1433–1434, 1989
  73. Braun WE: Nephrology Forum: Long-term complications of renal transplantation. Kidney Int 37:1363–1378, 1990 | PubMed | ISI | ChemPort |
  74. First MR: Long-term complications after transplantation. Am J Kidney Dis 22:477–486, 1993 | PubMed | ISI | ChemPort |
  75. Rao KV, Anderson WR: Liver disease after transplantation. Am J Kidney Dis 19:496–501, 1992 | PubMed |
  76. Rao KV, Anderson WR, Kasiske BL, Dahl DC: Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 94:241–250, 1993 | PubMed |
  77. Kirkman RL, Strom TB, Weir MR, Tilney NL: Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 34:347–351, 1982 | PubMed | ISI | ChemPort |
  78. Sengar DPS, Couture RA, Lazarovits AL, Jindal SL: Long term patient and renal allograft survival in HBsAg infection. Transplant Proc 21:3358–3359, 1989
  79. Rao KV, Anderson RC: Late morbidity and mortality associated with renal transplantation. Follow-up observations beyond the first decade. Transplant Proc 21:2163–2164, 1989
  80. Lefrancois N, Elmghabbar N, Chossegros P, Bethuel H, Faure JL, Revillard JP, Traeger J, Dubernard JM, Touraine JL: Long-term results in kidney transplantation: patient and graft survival, causes of graft failure and mortality, renal function and complications after 10 years. Transplant Proc 19:3767–3768, 1987
  81. Boletis J, Stathakis CH, Papastathi H, Stamatiadis D, Vafiadis E, Goumenos D, Kostakis A, Vosnides G: Hepatitis C virus infection in renal transplant patients, in Current Therapy in Nephrology, edited by Andreucci VE, Dal Canton A, Milano, Witchig Editore, 1992, p 539
  82. Chan T-M, Lok ASF, Cheng IKP, Chan RT: A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 104:862–868, 1993
  83. Roth D, Zucker K, Cirocco R, De Mattos A, Burke GW, Nery J, Esquenazi V, Babischkin S, Miller J: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 45:238–244, 1994 | PubMed |
  84. Morales JM, Munoz G, Castellano F, Colina A, Fuertes A, Andres A, Campo C, Blasco A, Hernandez E, Rodicio JL: Impact of hepatitis C in long-functioning renal transplants: A clinicopathological follow-up. Transplant Proc 25:1450–1453, 1993
  85. Hestin D, Hussenet F, Hubert J, Renoult E, Frimat L, Jacob C, Lefaou A, Kessler M: Hepatitis C following renal transplantation: Histopathological correlations. Transplant Proc 27:2468–2469, 1995
  86. Berthoux F: Hepatitis C virus infection and disease in renal transplantation. Nephron 71:386–394, 1995
  87. Pouteil-Noble C, Tardy JC, Chossegros P, Mion F, Chevallier M, Gerard F, Chevallier P, Megas F, Lefrancois N, Touraine JL: Co-infection by hepatitis B and hepatitis C virus in renal transplantation: Morbidity and mortality in 1098 patients. Nephrol Dial Transplant 10 (suppl 6):122–124, 1995
  88. Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C-Its prevalence in end stage renal failure patients and clinical course after kidney transplantation. Transplantation 55:273–276, 1993 | PubMed |
  89. Klauser R, Franz M, Traindl O, Pidlich J, Hay U, Watsch-Inger B, Pohanka E, Kovarik J: Hepatitis C antibody in renal transplant patients. Transplant Proc 24:286–288, 1992
  90. Pereira BJG, Wright TL, Schmid CH, Levey AS: The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 60:799–805, 1995 | PubMed |
  91. Boletis J, Deladetsima J, Psimenou E, Vafiadi I, Tzala E, Katsoulidou A, Kostakis A, Hatzakis A, Vosnides G: Liver biopsy is essential in anti-HCV (+) renal transplant patients irrespective of liver function tests and serology for HCV. Transplant Proc 27:945–947, 1995
  92. Chan T-M, Wu P-C, Lau JYN, Lai C-L, Lok ASF, Cheng IKP: Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 58:996–1000, 1994
  93. Glicklich D, Reinus J, Greenstein S, Schechner R, Mallis M, Clemetson S, Tellis V: Hepatitis C (HCV) infection in renal transplant (RT) recipients: Histology and clinical features. (abstract). J Am Soc Nephrol 5:1006, 1994
  94. Orloff SL, Stempel CA, Wright TL, Tomlanovich SJ, Amend WJC, Stock PG, Meltzer JS, Vincenti F: Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant 9:119–124, 1995
  95. Berthoux F, Haem J, Mosnier JF, Berthoux P, Cecillon S, Grattard F, Pozzetto B: Clear existence of hepatitis C virus (HCV) healthy carriers among renal transplant recipients (RTR). 7th Cong Eur Soc Organ Transplantation (ESOT), Vienna, October 1995, p 91
  96. Deladetsima JK, Boletis J, Makris F, Katsoulidoy A, Vafiadis I, Kostakis A, Hatzakis A, Vosnides G: Histopathology of HCV infection in renal transplant patients. (abstract). J Hepatol 23 (suppl 1):101, 1995
  97. Pol S, Legendre C, Saltiel C, Carnot F, Brechot C, Berthelot P, Mattinger B, Kreis H: Hepatitis C virus in kidney recipients, epidemiology and impact on renal transplantation. J Hepatol 15:202–206, 1992
  98. Morales JM: Hepatitis C and renal transplantation: Outcome of patients. Nephrol Dial Transplant 10 (suppl 6):125–128, 1995 | PubMed |
  99. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot P, Brechot C: Hepatitis C virus type Ib (II) infection in France and Italy. Ann Intern Med 122:161–168, 1995 | ChemPort |
  100. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJM, Williams R: Hepatic histologie findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13:150–157, 1991
  101. Lau JYN, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJM, Williams R: High level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 102:956–962, 1992
  102. Chen C-H, Chen P-J, Chu J-S, Yeh K-H, Lai M-Y, Chen D-S: Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology 107:1514–1518, 1994
  103. Booth JCL, Goldin RD, Brown JL, Karayiannis P, Thomas HC: Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant. J Hepatol 22:500–503, 1995
  104. Lim HL, Lau GKK, Davis GL, Dolson DJ, Lau JYN: Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 106:248–251, 1994
  105. Pouteil-Noble C, Tardy JC, Chossegros P, Doniamaged A, Ghezzi FM, Trepo C, Aymard M, Touraine JL: Anti hepatitis C antibodies: Prevalence and morbidity in renal transplantation, in Transplantation and Clinical Immunology (XXIII), edited by Touraine JL, Traeger J, Betuel H, Dubernard JM, Revillard JP, Dupuy C, Amsterdam, Excerpta Medica, 1991, p 81
  106. Alivanis P, Derveniotis V, Dioudis C, Grekas D, Mandravelli P, Vasiliou S, Tourkantonis A: Hepatitis C virus antibodies in hemodialysed and in renal transplant patients: Correlation with chronic liver disease. Transplant Proc 23:2662–2663, 1991
  107. Corell A, Morales JM, Mandrono A, Munoz MA, Andres A, Fuertes A, Arnaiz-Villena A: Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. Lancet 346:1497–1498, 1995
  108. Gumber SC, Chopra S: Hepatitis C: A multifaceted disease. Ann Intern Med 123:615–620, 1995
  109. Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, Davis C, Gretch DR: Renal manifestations of hepatitis C virus infection. Kidney Int 46:1255–1263, 1994 | PubMed | ISI | ChemPort |
  110. Morales JM, Fernandez-Zatarain G, Munoz A, Usera G, Fuertes A, Andres A, Rodicio JL: Clinical and immunological characteristics of allograft membranous glomerulonephritis in patients with hepatitis C infection after renal transplantation. 7th Cong Eur Soc Organ Transplantation (ESOT), Vienna, October 1995, p 92
  111. Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, Carreno M, Esquenazi V, Miller J: De novo membranoprolifera-tive glomerulonephritis in hepatitis C virus-induced renal allograft recipients. Transplantation 56:1676–1682, 1995
  112. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Sutzuki H, Tsuji T, Yano M, Kuo G, Ghoo Q-L, Houghton M, Oda T: A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 64:429–433, 1991
  113. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 21:650–655, 1995 | Article | PubMed | ISI | ChemPort |
  114. Demitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, Grigioni W, Alberti A, Beaugrand M, Pisi E, Brechot C, Paterlini P: HCV associated liver cancer without cirrhosis. Lancet 345:413–415, 1995 | Article | PubMed | ChemPort |
  115. Ferri C, La Civita L, Monti M, Longombardo G, Greco F, Pasero G, Zignego AL: Can type C hepatitis infection be complicated by malignant lymphoma? Lancet 346:1426–1427, 1995
  116. Huang C-C, Liaw Y-F, Lai M-K, Chu S-H, Chuang C-K, Hung J-Y: The clinical outcome of hepatitis C virus antibody positive renal allograft recipients. Transplantation 53:763–765, 1992 | PubMed |
  117. Zucker K, Cirocco R, Roth D, Burke G, Nevy J, Esquenazi V, Miller J: Prospective longitudinal assessment of hepatitis C virus infection after renal transplantation. Transplant Proc 27:943–944, 1995
  118. Black M: Alpha-interferon treatment of chronic hepatitis C: Need for accurate diagnosis in selecting patients. Ann Intern Med 116:86–88, 1992
  119. Peters M: Mechanism of action of interferons. Semin Liver Dis 9:235–239, 1989
  120. Abbas AK, Lichtman AH, Pober JS: Cytokines, in Cellular and Molecular Immunology, edited by , Abbas AK, Lichtman AH, Pober JS, Philadelphia, Saunders, 1994, p 240
  121. Kramer P, Ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W: Recombinant leucocyte interferon A induces steroid resistant acute vascular rejection episodes in renal transplantation. Lancet 1:989–990, 1984
  122. Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, Smolen J: Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 45:402–405, 1988
  123. Thervet E, Pol S, Legendre CH, Gagnadoux M-F, Cavalcanti R, Kreis H: Low-dose recombinant leucocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 58:625–627, 1994
  124. Rostaing L, Izopet J, Baron E, Duffaut M, Fuel J, Durand D, Suc JM: Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant recipients. Nephrol Dial Transplant 10 (suppl 6):93–96, 1995
  125. Ellis ME, Alfurayh O, Halim MA, Sieck JO, Ali MA, Bernvil SS, Ali H, Barri Y, Ayub A, Al-Fadda M: Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 18:210–216, 1993
  126. Raptopoulou M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vretou H, Vagionas G, Galaktidou G, Mavroudi I, Efkarpidou A, Kortsaris A: Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 10:1834–1837, 1995
  127. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C: Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialysis patients. Kidney Int 47:1412–1418, 1995
  128. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, PaYen JL, Sajus M, Costa JM, Vidaud M, Chaput JC: A comparison of three interferon alpha-2b regimens for long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457–1462, 1995
  129. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzutti F, Piperno A, Pozzi M, Ravizza D, Angelli G, Dianzani F, Mancia G: Breakthrough during recombinant interferon alpha therapy with chronic hepatitis C virus infection: Prevalence, etiology and management. Hepatology 21:645–649, 1995 | PubMed | ISI | ChemPort |
  130. Alter MJ, Sampliner RE: Hepatitis C and miles to go before we sleep. N Engl J Med 321:1538–1539, 1989
  131. Kumar M, Brown J, Monjadino J, Thomas HC: Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. Infect Dis 167:726–730, 1993
  132. Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S: The degree of variability in the aminoterminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619–624, 1992
  133. Zonaro A, Ravaggi A, Puoti M, Kremsdorf D, Albertini A, Cariani E: Differential pattern of sequence heterogeneity in the hepatitis C virus El and E2/NS1 proteins. J Hepatol 21:858–865, 1994
  134. Kumar U, Monjardino J, Thomas HC: Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agamma-globulinemic patient. Gastroenterology 106:1072–1075, 1994 | PubMed | ISI | ChemPort |
  135. Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, Gomez J: Dynamic behavior of hepatitis C quasispecies in patients undergoing orthotopic liver transplantation. J Virol 68:3425–3436, 1994 | PubMed | ISI | ChemPort |
  136. Hanrotel C, Brodart V, Toupance O, Dropsy C, Thiefin G, Diebold M, Ingrand D, Chanard J: Hepatitis C virus (HCV) genotypes in renal transplant recipients: A preliminary study (abstract). XXXII Cong ERA-EDTA, Athens, June 1995, p 309
  137. Kao JH, Chen PJ, Lai MY, Yang PM, Sheu JC, Wang TH, Chen DS: Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis. J Infect Dis 170:1128–1133, 1994
  138. Preston FE, Jarvis LM, Makris M, Philp L, Underwood JC, Ludlam CA, Simmonds P: Heterogeneity of hepatitis C virus genotypes in hemophilia: Relationship with chronic liver disease. Blood 85:1259–1262, 1995 | PubMed | ChemPort |
  139. Widdell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I: Hepatitis C superinfection in hepatitis C (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 60:642–647, 1995
  140. Bouthot B, Natov SN, Ruthazer R, Schmid CH, Levey AS, Pereira BJG: Impact of HCV infection on patient survival in patients referred for renal transplantation (abstract). 15th annual mtg, Am Soc Transplant Physicians, 1996, p 87
  141. Nakagiri I, Ichihara K, Ohmoto K, Hirokawa M, Matsuda N: Analysis of discordant test results among five second generation assays for anti-hepatitis C virus antibodies also tested by polymerase chain reaction-RNA assay and other laboratory and clinical tests for hepatitis. J Clin Microbiol 31:2974–2980, 1993 | ChemPort |
  142. Goodman ZD, Ishak KG: Histopathology of hepatitis C virus infection. Semin Liver Dis 15:70–81, 1995 | PubMed | ISI | ChemPort |
  143. Coelho-Little E, Jeffers LJ, Bartholomew M, Reddy KR, Schiff ER, Dailey PJ: Correlation of HCV-RNA levels in serum and liver of patients with chronic hepatitis C. J Hepatol 22:248–249, 1995
  144. Omata M, Yokosuka O, Takano S, Kato S, Hosoda K, Imazeki F, Tada Ito Y, Ohto M: Resolution of acute hepatitis C therapy with natural beta interferon. Lancet 338:914–915, 1991
  145. Takano S, Satomura Y, Omata M: Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized controlled-dose study. Gastroenterologe 107:805–811, 1994
  146. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakebashi R, Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S: Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 18:1319–1325, 1993
  147. Boletis J, Deladetsima J, Psimenou E, Makris F, Stamatiades D, Vafiadi E, Kostakis A, Hatzakis A, Vosnides G: Histological course of HCV in comparison to HBV liver disease in renal transplant patients (abstract). 7th Cong Eur Soc Organ Transplantation (ESOT '95, Vienna, October 1995, p 92
  148. Terrault NA, Wright TL: Hepatitis C virus in the setting of transplantation. Semin Liver Dis 15:92–100, 1995 | PubMed | ISI | ChemPort |
  149. Johnson RJ, Willson R, Yamabe H, Couser W, Alpers CE, Wener MH, Davis C, Gretch DR: Renal manifestations of hepatitis C virus infection. Kidney Int 46:1255–1263, 1994 | PubMed | ISI | ChemPort |
  150. Simon P, Ramee MP, Aautuly V, Laruelle E, Charasse C, Cam G, Ang KS: Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int 46:1192–1198, 1994 | PubMed | ISI | ChemPort |
  151. Rostoker G, Deforges L, Ben Maadi A, Remy P, Bourgeron B, Lang P, Weil B: Low prevalence of hepatitis C virus antibodies among adult patients with primary glomerulonephritis in France. Nephron 63:367, 1993 | PubMed |
  152. Pasquariello A, Ferri C, Moriconi L, La Civita L, Longoi-Bardo G, Lombardini F, Greco F, Zingego AL: Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Nephrol 13:300–304, 1993 | PubMed | ISI | ChemPort |
  153. Misiani R, Bellavita R, Fenili D, Borelli G, Marchesi D, Massazza M, Vendramin G, Comotti B, Tanzi E, Scudeller G, Zanetti A: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117:573–577, 1992 | PubMed | ISI | ChemPort |
  154. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Wilson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328:465–470, 1993 | Article | PubMed | ISI | ChemPort |
  155. Yamabe H, Fukushi K, Ohsawa H, Miyata M, Inuma H, Sasaki T, Kaizuka M, Tamura S, Tsunoda S, Fujida Y, Onodera K: Hepatitis C virus (HCV) infection may be an important cause of membrano-proliferative glomerulonephritis (MPGN) in Japan (abstract). J Am Soc Nephrol 4:2911, 1993
  156. Centers for Disease Control: Outbreaks of hepatitis B virus infection among hemodialysis patients—California, Nebraska and Texas, 1994. MMWR 45:285–289, 1996
  157. Pintos Dos Santos J, Loureiro A, Cendoroglo M, Pereira BJG: Impact of dialysis room and re-use strategies on the incidence of HCV infection in hemodialysis units. Nephrol Dial Transplant, in press
  158. Davis GL: Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 21:1–3, 1994
  159. Tassopoulos NC, Hatzakis AE, Papatheodoridis GN, Kar-Vounzis G, Troonen H, Lennartz L: Early prediction of successful therapy of chronic hepatitis C by core IgM antibodies to hepatitis C virus. J Hepatol 20:305–306, 1994
  160. Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, Longo DL: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 310:32–35, 1984 | PubMed | ISI | ChemPort |
  161. Lederer E, Truong L: Unusual glomerular lesions in a patient receiving long-term interferon alpha. Am J Kidney Dis 20:516–518, 1992
  162. Kimmel PL, Abraham AA, Phillips TM: Membranoproliferative glomerulonephritis in a patient treated with interferon-alpha for human immunodeficiency virus infection. Am J Kidney Dis 24:858–863, 1994 | PubMed | ISI | ChemPort |
  163. Schlaifer D, Dumazer P, Spenatto N, Mlgnon-Conte M, Brous-Set P, Lumbrosco C, Cooper M, Muller C, Huguet F, Altal M, Lauret G, Pris J: Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 47:254–255, 1994
  164. Greenfield SM, Harvey RS, Thompson RP: Rhabdomyolysis after treatment with interferon alpha. Br Med J 309:512, 1994
  165. Seef LB, Buskel-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perillo RP, Stevens CE, Hollingsworth CG: Long term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327:1906–1911, 1992
  166. Lam KC, Lai CL, Ng RP, Trepo C, Wu PC: Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 304:380–386, 1981
  167. Koretz RL: Hepatitis and renal disease, in Clinical Dialysis, edited by Nissenson AR, Fine RN, Gentile DE, Norwalk, Connecticut, Appleton and Lange, 1990, pp 366–390
  168. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, Merigan TC, Gregory PB: Survival in chronic hepatitis B: an analysis of 379 patients. Ann Intern Med 101:613–616, 1984

Extra navigation

.
ADVERTISEMENT